StonvexLoading…
StonvexStonvexStonvexCore line items from NDSN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2026 2026-04-30 | Q1 2026 2026-01-31 | Annual 2025 2025-10-31 | Q3 2025 2025-07-31 |
|---|---|---|---|---|
Revenue | $1.41B | $669.46M | $2.79B | $2.04B |
Operating Income | $363.61M | $166.41M | $711.73M | $497.46M |
Net Income | $250.70M | $133.38M | $484.47M | $332.84M |
EPS (Diluted) | $4.47 | $2.38 | $8.51 | $5.83 |
Total Assets | $5.96B | $5.96B | $5.92B | $6.01B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $102.02M | $120.39M | $108.44M | $147.79M |
Free Cash Flow OCF − CapEx | $293.41M | $122.92M | $661.12M | $467.26M |
Shares Outstanding | 56.11M | 56.13M | 55.92M | 57.08M |